Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Cancer Res. 2016 Nov 15;77(3):646–657. doi: 10.1158/0008-5472.CAN-15-3458

Figure 2. Loss of ULK1 function in the hypoxic tumor cells does not affect primary tumor growth.

Figure 2

a, Tumor volume of primary xenograft tumors over 7 weeks (mean ± s.d, n=15 mice per group). b, Quantification of primary tumor luciferase expression photon flux (photons/sec) in HRE-dnULK1 and HRE-Empty xenografts (mean ±SEM, n=15 mice per group). c, Representative images of luciferase expression from primary xenograft tumors over a 7 week time period. d, Representative images of tumors from HRE-dnULK1 and HRE-Empty orthotopic xenograft mice and quantification of final weight of excised primary tumors (mean ± s.d, n=15, ns=no significance, t-test). e, Immunoblot analysis of dnULK1 and p62 expression from 3 primary tumors from HRE-empty and HRE-dnULK1 xenografts (SE= short exposure, LE = Long Exposure, Asterisks (*)= p62 aggregate). f, Immunohistochemistry staining of primary tumors and lung serial sections from HRE-dnULK1 xenografts at week 7. Hypoxyprobe™ detects hypoxic areas within each tissue, which correlates to dnULK1 expression.